Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The monobactams.

N S Brewer1, W C Hellinger

  • 1Division of Infectious Diseases and Internal Medicine, Mayo Clinic Jacksonville, Florida.

Mayo Clinic Proceedings
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Aztreonam is a synthetic monobactam antibiotic effective against Gram-negative aerobic bacteria. It offers an alternative to aminoglycosides with a favorable safety profile, but its narrow spectrum requires combination therapy for severe infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-derived tuberculosis (TB) infection in lung transplant despite following recommended algorithm.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients.

Transplant infectious disease : an official journal of the Transplantation Society·2013
Same author

Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy.

Transplant infectious disease : an official journal of the Transplantation Society·2013
Same author

Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Association of surgeon with surgical site infection after liver transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Healthcare-associated hepatitis C virus transmission among patients in an abdominal organ transplant center.

Transplant infectious disease : an official journal of the Transplantation Society·2009
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Monobactam antibiotics are synthetic beta-lactam compounds.
  • Aztreonam is the first marketed monobactam, with a spectrum similar to aminoglycosides.
  • Aztreonam exhibits a favorable safety profile, lacking nephrotoxicity and coagulation issues associated with aminoglycosides.

Purpose of the Study:

  • To review the properties and clinical applications of aztreonam.
  • To highlight aztreonam's pharmacokinetic profile and dosing recommendations.
  • To discuss the spectrum of activity and limitations of aztreonam.

Main Methods:

  • Literature review of aztreonam's pharmacology and clinical data.
  • Analysis of aztreonam's antimicrobial spectrum, pharmacokinetics, and safety.

Related Experiment Videos

  • Evaluation of approved indications and recommended usage in clinical practice.

    • Main Results:

    • Aztreonam demonstrates excellent activity against Gram-negative aerobic bacteria.
    • It is administered via intramuscular or intravenous routes, with renal excretion as the primary elimination pathway.
    • Aztreonam has a serum half-life of 1.5–2.1 hours in patients with normal renal function, requiring dosage adjustments for renal impairment.

    Conclusions:

    • Aztreonam is a valuable antibiotic for Gram-negative aerobic infections, particularly when aminoglycoside toxicity is a concern.
    • Its strictly Gram-negative aerobic spectrum necessitates combination therapy for seriously ill patients at risk for other pathogens.
    • Approved indications include various infections, underscoring its role in treating susceptible bacterial infections.